KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.95

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.

Robert J Motzer, Paul Russo, Viktor Grünwald, Yoshihiko Tomita, Bogdan Zurawski, Omi Parikh, Sebastiano Buti, Philippe Barthélémy, Jeffrey C Goh, Dingwei Ye, Alejo Lingua, Jean-Baptiste Lattouf, Laurence Albigès, Saby George, Brian Shuch, Jeffrey Sosman, Michael Staehler, Sergio Vázquez Estévez, Burcin Simsek, Julia Spiridigliozzi, Aleksander Chudnovsky, Axel Bex

Target Oncol 18(5) 639-641

PMID37659025
PMCIDPMC10517884
DOI10.1007/s11523-023-00987-1
发表日期2023-09-02
入排依据:Meets all eligibility criteria: Phase 3 randomized trial in human oncology with a drug intervention and primary time-to-event efficacy endpoint.
摘要

摘要

This is a summary of a research article reporting Part A of the CheckMate 914 study (NCT03138512; EudraCT 2016-004502-34). Following surgery to remove renal cell carcinoma (RCC), people with a high risk of the cancer returning received nivolumab plus ipilimumab (adjuvant therapy) or placebo to see if this risk was reduced. The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. In addition, people treated with nivolumab plus ipilimumab had more side effects compared with people treated with placebo (89% versus 57%).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。